Premium
RESULTS FROM THE SAFETY RUN‐IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Author(s) -
Wang M.,
Ramchandren R.,
Chen R.,
Karlin L.,
Chong G.,
Jurczak W.,
Wu K.,
Bishton M.,
Collins G.,
Eliadis P.,
Peyrade F.,
Freise K.,
Sukbuntherng J.,
Lee Y.,
Dobkowska E.,
Fedorov V.,
Neuenburg J.,
Tam C.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.146_2630
Subject(s) - ven , medicine , mantle cell lymphoma , ibrutinib , tumor lysis syndrome , adverse effect , lymphoma , gastroenterology , refractory (planetary science) , placebo , oncology , urology , chemotherapy , pathology , leukemia , chronic lymphocytic leukemia , physics , alternative medicine , computer security , astrobiology , computer science